NLX-112 as a potential first-in-class, no... - Cure Parkinson's
NLX-112 as a potential first-in-class, non-dopaminergic therapy that reduces both ldopa-induced dyskinesia and motor impairment in PD
Study here: movementdisorders.onlinelib...
"NLX-112 reduced LID [Levodopa induced dyskinesia] from baseline levels: at day 42, UDysRS total score decreased by 6.3 points, whereas placebo group changes were not significant (−2.4). NLX-112 also reduced parkinsonism from baseline values: UPDRS Part 3 scores decreased by 3.7 points, whereas placebo group changes were non-significant (+0.1). In CGI-C assessment, the NLX-112 group showed greater improvement than the placebo group (53% vs. 29%)."
Looks like this will be helpful.Still need to do a phase III trial and get approval.
Looks hopeful, but what's troubling is that the study seemed to have been completed two years ago (March 2023) and the molecule does not appear to have progressed since. I wonder is the delay due to funding issues?
Do not know but that is certainly a possibility.
This seems to be very promising
